Home | XHANCE® (fluticasone propionate)

IMAGINE

if sinus symptoms took control of your days (and nights).

Now, reimagine treating nasal polyposis with XHANCE—the only nasal polyp therapy using the Exhalation Delivery System™ to treat inflammation high and deep.^1-3

See the Exhalation Delivery
System (EDS^®) of XHANCE

See how XHANCE delivers
medication high and deep

See the impact of XHANCE on
patients in the 2 pivotal trials

Diagnosis of Nasal Polyps

Many patients with chronic rhinosinusitis (CRS) may develop nasal sessile or pedunculated polyps as the disease progresses from polypoid tissue^3,4
If 2 or more symptoms—including nasal congestion, loss of smell, nasal discharge, facial pain, or pressure—persist after standard nasal steroids, it’s potentially polyps^5,6

Deposition

Standard nasal steroids predominately deliver to the anterior nasal cavity with minimal deposition above and behind the turbinates, ostiomeatal complex, and superior nasal regions, where most polyps originate.^3,7-9

XHANCE Clinical Results

XHANCE significantly improved congestion and nasal polyp grade, regardless of prior experience with standard nasal steroids.^1,2,10

Average improvement in congestion in a clinical trial using a 0-3 point scale: 0.62 XHANCE 372 mcg BID vs 0.24 EDS-placebo (P<0.001) at Week 4^1,2
Average reduction in bilateral polyp grade in a clinical trial using a 0-3 point scale: 1.41 XHANCE 372 mcg BID vs 0.61 EDS-placebo (P<0.001) at Week 16^1,2

Graphic of XHANCE SAVINGS CARD. Receive Your Initial Prescription For as Little as $0*. *See back of card for terms and conditions

Affordability

Most commercially insured patients pay $0-$25 per month using the Preferred Pharmacy Network (PPN).*

*These offers are not valid for use by cash-paying patients or patients enrolled in Medicare, Medicaid, and TRICARE or other federal or state programs. Offers are subject to quantity limitations. Maximum benefits per fill apply. Patient cost share may impact benefits and eligibility. Optinose® reserves the right to rescind, revoke, or amend this offer without notice. See XHANCE.com/terms-and-conditions for additional terms and conditions.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:
Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local Nasal Adverse Reactions: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Close monitoring for glaucoma and cataracts is warranted.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and Risk of Infection: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care.

ADVERSE REACTIONS:
The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS:
Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS:
Hepatic impairment. Monitor patients for signs of increased drug exposure.

INDICATION
XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients 18 years of age or older.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

References:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2023.
Leopold DA, Elkayam D, Messina JC, et al. NAVIGATE II: randomized double-blind trial of the exhalation delivery system with fluticasone for nasal polyposis. J Allergy Clin Immunol. 2019;143(1):126-134.e5.
Larsen PL, Tos M. Origin of nasal polyps: an endoscopic autopsy study. Laryngoscope. 2004;114(4):710-719.
Ryu G, Bae JS, Kim JH, et al. Role of IL-17A in chronic rhinosinusitis with nasal polyps. Allergy Asthma Immunol Res. 2020;12(3):507-522.
Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
Han JK, Bosso JV, Cho SH, et al. Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021:11(10):1407-1416.
Leach CL, Kuehl PJ, Chand R, McDonald JD. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients. J Aerosol Med Pulm Drug Deliv. 2015;28(5):334-340.
Zhong C, Jiang Z, Zhang X. Effect of distribution of nasal polyps in ostiomeatal complex on long-term outcomes after endoscopic surgery. Eur Arch Otorhinolaryngol. 2015;272(12):3757-3762.
Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res. 2013;3(1):42-62.
Senior BA, Schlosser RJ, Bosso J, Soler ZM. Efficacy of the exhalation delivery system with fluticasone in patients who remain symptomatic on standard nasal steroid sprays. Int Forum Allergy Rhinol. 2021;11(5):837-845.